Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Adv Drug Deliv Rev. 2022 May 23;187:114358. doi: 10.1016/j.addr.2022.114358

Table 1.

In vivo adapter dosing schedule for adapter-mediated CAR T platform tumor killing.

Ref CAR/Adapter Cell line CAR Cell # Infused Adapter Dose Timing
[21] Biotin receptor/Streptavidin A1847 ovarian cancer cells BBIR CAR 6 × 106 Bio-EpCAM Ab 100 ng On days 45, 56, 60
[31] Anti-FITC scFv/FITC Nalm-6 B-ALL cancer cells Anti-FITC sCAR 40 × 106 Bivalent FITC
anti-CD19 fab switch		 0.5 mg/kg Every other day, six doses total
[112] Anti-GCN4 scFv/GCN4 peptide Nalm-6 B-ALL cancer cells Anti-GCN4 sCAR 40 × 106 Bivalent GCN4
anti-CD19 fab
switch		 0.5 mg/kg Every day for 10 days
[42] 5B9 scFv/5B9 peptide A431 EGFR+ cells UniCAR 5 × 106 Anti-EGFR scFv 100 ug Single dose
[16] SpyCatcher/SpyTag SKOV ovarian cancer cells SpyCatcher CAR (preloaded with 1 uM Herceptin-ST) 12.5 × 106 Herceptin-ST 25 ug Every 3 days for 40 days
[82] SUPRA CAR SK-BR-3 Her2+ breast cancer cells zipCAR 10 × 106 Anti-Her2 zipFv 5 mg/kg Every 2 days for 2 weeks
[82] SUPRA CAR Her2+ Jurkat T cells zipCAR 10 × 106 Anti-Her2 zipFv 3 mg/kg Every day for 6 days
[89] ConvertibleCAR Raji CD19+ cancer cells iNKGD2 CAR 35 × 106 Rit-S3 60 ug Single dose